Veloxis Patent-Cliff Exposure & CMS Drug Spending Portfolio

Veloxis (US): 1 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $64.0M 2024 CMS Part D & Medicaid spend, and 18 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure100.0%
Primary Portfolio LOE Date2028-01-01
2024 CMS Total Public Spend$64.0M
2024 Medicare Part D Spend$16.9M
2024 Medicaid Spend$47.2M
California HCAI SB 17 Filings18 WAC filings (max 20.0% 2-yr change)